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We describe a patient with node positive prostate cancer treated with radiation, androgen deprivation, and immunotherapy with
long-term overall survival and PSA control. ELISPOT immunoassay studies demonstrated PSA speciﬁc T-cells prior to starting
vaccine therapy suggesting that this positive response may be related to an improved antitumor immune response of the patient,
increased immunogenicity of the tumor, or decreased activation of immune escape pathways. Further evaluation of therapeutic
cancervaccinesincombinationwithradiationandhormonaltherapyinthedeﬁnitivemanagementofprostatecanceriswarranted.
Copyright © 2009 National Cancer Institute, National Institutes of Health (NIH/NCI). This is an open access article distributed
under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.
1.Introduction
Men with newly diagnosed node positive prostate cancer
have a higher likelihood of developing progressive disease
and dying from prostate cancer than men without lymph
node involvement [1]. The current standard of care for
these men includes a combined modality approach with
radiation and androgen deprivation therapy to address both
locoregional and systemic disease. Results with this approach
are not ideal and the addition of other modalities, such as
immunotherapy, to radiation and hormonal treatment may
improve treatment outcomes [2].
We present a case report on a node positive prostate
cancer patient treated with immunotherapy, radiation, and
androgen deprivation with long-term overall survival and
PSA control.
Case. This patient is a 59-year-old male who initially
presented with signs and symptoms of prostatitis. PSA
ordered as part of his work-up was 95µg/L. He was treated
with 2 courses of antibiotics, after which a repeat PSA
was 95µg/L. A subsequent transrectal ultrasound-guided
biopsy revealed adenocarcinoma of the prostate in 7/8c o r e s ,
with Gleason score 4 + 3 being the highest grade seen.
Further evaluation included a computed tomography scan
of the abdomen and pelvis, magnetic resonance imaging
of the pelvis showing a normal-sized prostate with no
evidence of extracapsular extension, a periprostatic lymph
node measuring 1.8cm, a left iliac lymph node measuring
2.5 × 3.8 × 3.8cm (Figure 1), and a normal bone scan.
Digital rectal examination demonstrated an abnormality in
more than half of one lobe but not both. The remainder of
his physical examination, laboratory tests, and history was
unremarkable. The patient was clinically staged as Stage IV
(T2bN1M0).
The patient was subsequently enrolled on a randomized
phase 2 clinical trial at the National Cancer Institute, where
he was treated with a priming vaccine of recombinant
vaccinia virus engineered to encode PSA admixed with a
recombinant vaccinia virus encoding the T-cell costimula-
tory molecule B7.1. This was followed by monthly boosts
with a recombinant fowlpox vector expressing PSA, for a
total of 8 vaccinations [3]( Figure 2). The vaccines were
givenwithlocalgranulocyte-macrophagecolony-stimulating
factor and systemic low-dose interleukin-2 (4MIU/M2).
External beam radiation therapy was given between the
fourth and sixth vaccinations. The patient was treated using
3D conformal radiation therapy to a dose of 75.6Gy, with
the left iliac lymph node receiving 59.4Gy. He was started2 Clinical and Developmental Immunology
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Figure 1: Axial and sagittal magnetic resonance images showing an enlarged left external iliac lymph node (white arrow axial, black arrow
sagittal).
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Figure 2: Three monthly vaccines were given before external beam
radiation therapy (EBRT, thick line). The initial vaccine was given
with an admixture of rV-PSA and rV-B7.1 with follow-up monthly
boosts given with recombinant fowlpox PSA. Immunologic studies
were performed prevaccination, post-3, post-4, post-5, and post-8
cycles of vaccine (designated by the arrows).
on bicalutamide and goserelin prior to starting radiation
therapy and continues on this regimen.
At his last follow-up, 98-month postradiation treatment,
the patient’s PSA was <0.04µg/L.
2. Methods
Correlative immunologic studies were performed that mea-
sured PSA-speciﬁc T cells with ELISPOT prevaccination,
post-3, post-4, post-5, and post-8 cycles of vaccine as
previously described [2].
3. Results andDiscussion
Mature biochemical progression data from the trial the
patient in this case study was enrolled on are not yet
available. Among the 8 patients with node-positive disease
enrolledonthestudyhowever,5havedevelopedbiochemical
progression at 1, 7, 58, and 68 months. We do not have
the exact progression date for the ﬁfth patient but know
that he progressed within 48 months from the end of
his radiation treatment. The other 2 patients have not
had biochemical progression as of follow-up at 63 and 71
months. Immunologic studies were performed on 4 of the
node-positive patients, and the patient presented here is
the only one of the 4 who has not developed biochemical
progression. Interestingly, he is the only patient among this
group to have PSA-speciﬁc T cells (i.e., >1: 100,000) prior to
starting vaccine and the most vigorous T-cell response post
vaccination (Table 1).
This may suggest that, compared to others in the group,
this patient’s tumor may have had more HLA class I and
II molecules loaded with relevant prostate cancer-associated
antigens making immune detection of the tumor easier
(more immunogenic), there was more upregulation of fas on
thetumor(makingiteasiertokillimmunologically),orthere
was decreased negative immune regulation. Interestingly, his
level of Treg cells (CD4+CD25highFoxp3+) was not elevated
(2.1% of CD4 cells) [5]. Furthermore, additional testing
showed that his PSA-speciﬁc T-cell response remained
detectable (between 1/13,953 and 1/86,714) at each time
point tested (3, 6, 12, and 24 months) following completion
of vaccine. It is also possible that by boosting an already
present relevant antitumor immune response, he may have
beneﬁtedmorefromimmunotherapythantheotherpatients
without a baseline antitumor immune response.
While this hypothesis is intriguing, these 4 patients did
have diﬀerent baseline characteristics (Table 2).
This patient’s PSA was higher than the group median
of 41µg/L; however, he received a slightly higher dose of
radiation compared to the median 72.9Gy and was the only
patient who received a radiation boost to his involved lymph
node. He also had a Gleason score of 7, which was lower
than the scores of 8 to 9 for the other 3 patients. In addition,
he has been on androgen deprivation with bicalutamide and
goserelin since his diagnosis (about 7.5 years) whereas the
longest time of hormone treatment, with either goserelin
alone or goserelin and bicalutamide, for the other three
patients was 2 years. These diﬀerences preclude drawing
any deﬁnite conclusions regarding whether this patient truly
beneﬁted from vaccine therapy. However, it is noteworthy
that the only node-positive patient with PSA-reactive T cells
prior to starting vaccine is the only one who is still PSA
failure-free at 98 months.Clinical and Developmental Immunology 3
Table 1: ELISPOT PSA-speciﬁc T cells for patients with node positive disease at various time points during vaccination. Patient 1 is the
only patient with detectable PSA-speciﬁc T cells prior to starting vaccination. It should be noted that the post-4 immune responses were
obtained mid-radiation, and unlike the other time points, this blood was prepared from a peripheral blood draw rather than an apheresis
sample. Interestingly, radiation has been shown to upregulate markers on the tumor facilitating tumor speciﬁc T-cell traﬃcking which may
impact peripheral circulation of antigen speciﬁc T-cells (reviewed in [4]). It is possible that either of these variables could have impacted the
measured immune response. ∗Post-2 cycles.
Time Point Patient 1 Patient 2 Patient 3 Patient 4
Pre-vaccine 1/50,000 1/200,000 <1/200,000 1/150,000
Post-3 cycles 1/37,500 1/54,545 1/50,000 <1/200,000
∗
Post-4 cycles <1/200,000 <1/200,000 <1/200,000 Data not available
Post-5 cycles 1/24,000 1/66,667 <1/200,000 1/12,000
Post-8 cycles 1/15,789 1/22,222 1/46,154 Data not available
Table 2: Baseline patient characteristics and clinical/PSA failure status for patients with immunologic data and node positive disease.
Patient # Age at diagnosis






1 51 T2bN1M0 7 95 75.6 No
2 56 T2cN1M0 9 5 70.2 Yes
3 56 T2cN1M0 8 63 68.0 Yes
4 55 T2aN1M0 8 19 75.6 Yes
There are limited long-term data on patients with node-
positive prostate cancer treated with radiation therapy. The
Radiation Therapy Oncology Group (RTOG) 75-06 study
treated patients with node-positive prostate cancer with
radiation therapy to either a pelvic or pelvic plus para-aortic
ﬁeld. At 10 years, 5/90 patients were alive and clinically
free of cancer without hormone therapy [6]. In a follow-
up study, RTOG 85-31 randomized men to immediate
androgen suppression with radiation versus radiation alone
and hormonal therapy started at time of relapse. This
study included a subset of 173 node-positive prostate cancer
patients. Within this group, those who received immediate
hormone therapy were more likely to have a PSA <1.5ng/mL
at 9 years versus those who received delayed hormone
therapy (10% versus 4%, P<. 0001) [7]. While adding
hormones to radiation therapy certainly improves outcomes,
there is much room for improvement.
Immunotherapy may be a promising option for achiev-
ing this outcome. Results from IMPACT (Immunotherapy
for Prostate AdenoCarcinoma Treatment), a randomized
phase 3 study of Provenge (sipuleucel-T) versus placebo in
metastatic androgen-independent prostate cancer, showed
a signiﬁcant survival beneﬁt of 4.1-month median overall
survival for patients receiving Provenge [8]. Furthermore,
a multicenter-randomized controlled phase II study of
PROSTVAC (a similar vaccine to the one described here
but with additional costimulatory molecules) demonstrated
an 8.5-month improvement in median overall survival, the
secondary endpoint of the study, in patients with metastatic
castration resistant prostate cancer [9] .T h e r ei sa l s oa
suggestion that patients treated with lower volumes of
prostate cancer may have a larger survival beneﬁt with
immunotherapy [10]. Whether immunotherapy plus radia-
tion and hormonal therapy for men with localized or locally
advanced prostate cancer oﬀers an advantage to standard
treatment alone is currently unknown.
The patient in this case report had reactive T-cells prior
to vaccine administration and is the only one of the node
positive patients on trial who is still PSA failure free. While it
is not proved clearly, this suggests that patients with intact
immune surveillance mechanisms may be more likely to
respond to treatment with immunotherapy.
4. Conclusions
Given the recent survival beneﬁt seen with immunother-
apy in metastatic prostate cancer patients, the role of
immunotherapy in a deﬁnitive setting with standard treat-
ments merits further investigation.
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